Barry E. Gidal

5.2k total citations · 1 hit paper
104 papers, 2.7k citations indexed

About

Barry E. Gidal is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Barry E. Gidal has authored 104 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Psychiatry and Mental health, 66 papers in Pediatrics, Perinatology and Child Health and 20 papers in Oncology. Recurrent topics in Barry E. Gidal's work include Epilepsy research and treatment (78 papers), Pharmacological Effects and Toxicity Studies (60 papers) and Neuroscience and Neuropharmacology Research (18 papers). Barry E. Gidal is often cited by papers focused on Epilepsy research and treatment (78 papers), Pharmacological Effects and Toxicity Studies (60 papers) and Neuroscience and Neuropharmacology Research (18 papers). Barry E. Gidal collaborates with scholars based in United States, United Kingdom and Sweden. Barry E. Gidal's co-authors include Raj D. Sheth, Gilmour Morrison, Lesley Taylor, Graham Blakey, Bola Tayo, Bruce P. Hermann, Jacqueline A. French, Michael Seidenberg, Michael E. Pitterle and Austin Woodard and has published in prestigious journals such as Neurology, Epilepsia and Clinical Pharmacokinetics.

In The Last Decade

Barry E. Gidal

97 papers receiving 2.6k citations

Hit Papers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, ... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
    2018 341 citations Barry E. Gidal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barry E. Gidal United States 30 1.6k 1.3k 670 561 266 104 2.7k
Kenneth W. Sommerville United States 29 1.8k 1.1× 1.1k 0.8× 618 0.9× 705 1.3× 232 0.9× 64 2.8k
Vicente Villanueva Spain 30 2.3k 1.5× 1.7k 1.2× 1.2k 1.8× 640 1.1× 412 1.5× 143 3.3k
John A. Messenheimer United States 33 2.5k 1.6× 2.2k 1.7× 703 1.0× 469 0.8× 414 1.6× 87 3.8k
Cecilie Johannessen Landmark Norway 27 2.0k 1.3× 1.8k 1.4× 510 0.8× 404 0.7× 119 0.4× 80 2.8k
Angela K. Birnbaum United States 29 1.3k 0.8× 1.5k 1.2× 420 0.6× 394 0.7× 113 0.4× 110 2.8k
Peter M. Edelbroek Netherlands 29 1.3k 0.8× 1.0k 0.8× 511 0.8× 500 0.9× 157 0.6× 63 3.0k
Tsuyoshi Kondo Japan 30 1.4k 0.9× 613 0.5× 358 0.5× 339 0.6× 221 0.8× 158 2.6k
Marc Kamin United States 31 1.8k 1.2× 1.1k 0.9× 847 1.3× 1.1k 2.0× 454 1.7× 61 4.0k
Frank Vajda Australia 38 2.7k 1.7× 3.3k 2.4× 601 0.9× 296 0.5× 202 0.8× 167 5.0k
Alan R. Kugler United States 20 742 0.5× 674 0.5× 417 0.6× 293 0.5× 100 0.4× 39 1.8k

Countries citing papers authored by Barry E. Gidal

Since Specialization
Citations

This map shows the geographic impact of Barry E. Gidal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry E. Gidal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry E. Gidal more than expected).

Fields of papers citing papers by Barry E. Gidal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry E. Gidal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry E. Gidal. The network helps show where Barry E. Gidal may publish in the future.

Co-authorship network of co-authors of Barry E. Gidal

This figure shows the co-authorship network connecting the top 25 collaborators of Barry E. Gidal. A scholar is included among the top collaborators of Barry E. Gidal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry E. Gidal. Barry E. Gidal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shafer, Patricia Osborne, et al.. (2024). Intranasal Delivery of Medications for the Treatment of Neurologic Conditions: A Pharmacology Update. Journal of Neuroscience Nursing. 56(4). 136–142.
2.
Barnard, Sarah, Zhibin Chen, Andrés M. Kanner, et al.. (2024). The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy. Neurology. 103(7). e209821–e209821. 5 indexed citations
3.
Barnard, Sarah, Shruti Agashe, Manisha Holmes, et al.. (2023). Patterns of antiseizure medication utilization in the Human Epilepsy Project. Epilepsia. 64(12). 3196–3204.
4.
Gidal, Barry E., et al.. (2023). Patterns of psychotropic drug use in veterans with epilepsy: Do drug interactions matter?. Epilepsy & Behavior. 145. 109335–109335.
5.
Gidal, Barry E., et al.. (2023). Zonisamide. Neurology Clinical Practice. 14(1). e200210–e200210. 8 indexed citations
6.
Wheless, James W., Barry E. Gidal, Adrián L. Rabinowicz, & Enrique Carrazana. (2023). Practical Questions About Rescue Medications for Acute Treatment of Seizure Clusters in Children and Adolescents with Epilepsy in the USA: Expanding Treatment Options to Address Unmet Needs. Pediatric Drugs. 26(1). 49–57. 2 indexed citations
7.
Kotloski, Robert J. & Barry E. Gidal. (2022). Rescue Treatments for Seizure Clusters. Neurologic Clinics. 40(4). 927–937. 2 indexed citations
8.
9.
Gidal, Barry E., Pavel Klein, & Lawrence J. Hirsch. (2020). Seizure clusters, rescue treatments, seizure action plans: Unmet needs and emerging formulations. Epilepsy & Behavior. 112. 107391–107391. 31 indexed citations
10.
Klein, Pavel, Dwain Tolbert, & Barry E. Gidal. (2019). Drug–drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy & Behavior. 99. 106459–106459. 28 indexed citations
11.
Isojärvi, Jouko, Barry E. Gidal, Steve Chung, & Robert Wechsler. (2017). Optimizing clobazam treatment in patients with Lennox–Gastaut syndrome. Epilepsy & Behavior. 78. 149–154. 10 indexed citations
12.
Gidal, Barry E., et al.. (2017). When adverse effects are seen as desirable: Abuse potential of the newer generation antiepileptic drugs. Epilepsy & Behavior. 77. 62–72. 9 indexed citations
13.
Gidal, Barry E., et al.. (2017). Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. Epilepsy Research. 135. 64–70. 7 indexed citations
14.
15.
Hussein, Ziad, Barry E. Gidal, Haichen Yang, et al.. (2015). Pharmacokinetic, Pharmacodynamic and Cognitive Effects of Adjunctive Perampanel in Adolescents With Inadequately Controlled Partial Seizures (P1.255). Neurology. 84(14_supplement). 1 indexed citations
16.
Fine, Perry G., David H. Bradshaw, Mitchell J. Cohen, et al.. (2014). Evaluation of the Performance Improvement CME Paradigm for Pain Management in the Long-Term Care Setting. Pain Medicine. 15(3). 403–409. 4 indexed citations
17.
Gidal, Barry E., Oneeb Majid, Jim Ferry, et al.. (2014). The practical impact of altered dosing on perampanel plasma concentrations: Pharmacokinetic modeling from clinical studies. Epilepsy & Behavior. 35. 6–12. 25 indexed citations
18.
Gidal, Barry E., et al.. (2003). Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Research. 57(2-3). 85–93. 64 indexed citations
19.
Rutecki, Paul & Barry E. Gidal. (2002). Antiepileptic drug treatment in the developmentally disabled: treatment considerations with the newer antiepileptic drugs. Epilepsy & Behavior. 3(6). 24–31. 13 indexed citations
20.
Gidal, Barry E., et al.. (1993). Evaluation of the Effect of Fluoxetine on the Formation of Carbamazepine Epoxide. Therapeutic Drug Monitoring. 15(5). 405–409. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth W. Sommerville Breakdown of academic impact, for papers by Vicente Villanueva Breakdown of academic impact, for papers by John A. Messenheimer Breakdown of academic impact, for papers by Cecilie Johannessen Landmark Breakdown of academic impact, for papers by Angela K. Birnbaum Breakdown of academic impact, for papers by Peter M. Edelbroek Breakdown of academic impact, for papers by Tsuyoshi Kondo Breakdown of academic impact, for papers by Marc Kamin Breakdown of academic impact, for papers by Frank Vajda Breakdown of academic impact, for papers by Alan R. Kugler
Rankless by CCL
2026